Skip to main content
SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD logo

SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD — Investor Relations & Filings

Ticker · 002737 ISIN · CNE100001WT7 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,262 across all filing types
Latest filing 2025-10-10 Governance Information
Country CN China
Listing Shenzhen Stock Exchange 002737

About SUNFLOWER PHARMACEUTICAL GROUP CO.,LTD

https://www.kuihuayaoye.com

Sunflower Pharmaceutical Group Co., Ltd. focuses on the research, development, manufacturing, and distribution of proprietary Chinese medicines, chemical drugs, and health supplements. The organization is particularly noted for its specialization in pediatric medicine, marketed under the "Little Sunflower" brand, which includes treatments for respiratory and digestive ailments. Its extensive product portfolio also covers gynecological health and general internal medicine. The group operates several integrated production bases and research institutes, facilitating a comprehensive approach to drug formulation and quality control. By leveraging a robust supply chain and a wide-reaching distribution network, the company provides a diverse range of over-the-counter and prescription solutions aimed at improving family health and wellness.

Recent filings

Filing Released Lang Actions
对外提供财务资助管理制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled as a management system or policy document regarding the company's external financial assistance management. It outlines rules, procedures, and governance related to financial support provided by the company to external parties. There are no financial statements, no earnings data, no audit opinions, no voting results, no legal proceedings, no capital changes, no merger or acquisition details, and no conference call transcripts. The document is a governance or internal control policy document issued by the board and approved by shareholders. It is not a report or announcement of financial results or regulatory filings. Therefore, the best fitting category is Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices.
2025-10-10 Chinese
对外担保管理制度（2025年10月）
Governance Information Classification · 95% confidence The document is titled as a management system for external guarantees by the company 葵花药业集团股份有限公司. It details internal control procedures, approval processes, risk control, and responsibilities related to the company's external guarantee activities. There is no financial data, no financial statements, no earnings information, no voting results, no legal proceedings, no capital changes, no audit reports, no presentations, and no announcements of report publications. The document is a governance-related internal policy document outlining rules and procedures for managing external guarantees. This fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices. The document length is about 4946 characters, which is substantive and not a mere announcement or certification. Therefore, the classification is CGR with high confidence.
2025-10-10 Chinese
关于使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a public announcement by a company (葵花药业集团股份有限公司) regarding the progress of using idle self-owned funds for cash management. It details the amounts invested, types of financial products, risk control measures, and the impact on the company. The document is titled as an "announcement" and does not contain comprehensive financial statements or detailed financial performance data. It is a regulatory disclosure about financing activities related to cash management, not a full financial report or earnings release. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length is about 9,867 characters, which is substantial but the content is focused on cash management progress and investment details rather than a full report or earnings summary.
2025-09-11 Chinese
关于盐酸非索非那定口服混悬液获得药品注册证书的公告
Regulatory Filings Classification · 95% confidence The document is an official announcement from a pharmaceutical company about receiving a drug registration certificate from the national drug regulatory authority. It details the drug's name, composition, registration classification, approval number, and intended use. The document includes a risk warning related to the product launch and investment risks. It does not contain financial statements, management discussion, or detailed financial data. The document length is short (1086 characters) and serves as a formal announcement of regulatory approval rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which covers general regulatory announcements and compliance documents that do not fit other categories.
2025-09-01 Chinese
2025年半年度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled as the "2025 年半年度报告全文" which translates to the "2025 Semi-Annual Report Full Text". It contains detailed financial data, management discussion and analysis, company overview, financial indicators, and operational details for the period January 1, 2025 to June 30, 2025. The length is substantial (15,000 characters), and it includes actual financial statements and substantive financial data and analysis. This matches the definition of an Interim / Quarterly Report (IR). It is not a brief announcement or a certification, but a full report. Therefore, the document should be classified as an Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese
半年度非经营性资金占用及其他关联资金往来情况汇总表
Interim / Quarterly Report Classification · 95% confidence The document is a detailed financial summary table regarding non-operating fund occupation and other related party fund transactions for the half-year period of 2025. It includes specific financial figures, accounting subjects, and relationships with related parties. The document is signed off by company officials and approved by the board, indicating it is an official financial disclosure. The content is specific to a half-year period and contains substantive financial data, which aligns with an Interim / Quarterly Report rather than a brief announcement or a regulatory filing. The document length is under 5,000 characters but contains actual financial data, so it is not a mere announcement. Therefore, the most appropriate classification is Interim / Quarterly Report (IR). H1 2025
2025-08-27 Chinese

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.